Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Enobia Pharma, a biotech company focused on developing novel therapeutics for serious bone disorders, has received the orphan drug designation from the FDA for ENB-0040, its enzyme replacement therapy for hypophosphatasia, a rare, life-threatening genetic bone disease.
Subscribe to our email newsletter
The orphan drug designation will entitle Enobia to a seven-year period of marketing exclusivity for the drug upon FDA approval, as well as the opportunity to apply for funding from the US government to defray costs of clinical trial expenses, tax credits for clinical research expenses and potential waiver of the FDA’s application user fee.
Robert Heft, CEO of Enobia, said: “ENB-0040 represents a potential drug therapy for the patients with hypophosphatasia, an under-recognized disease that can be fatal in infants and cause serious disability in older patients that has no currently approved FDA treatment. The recent dosing of the first adult hypophosphatasia patient in our Phase I clinical trial and receipt of orphan drug designation are important milestones for this program.”
The FDA grants orphan drug designation to encourage biotechnology and pharmaceutical companies to develop products that demonstrate promise for the treatment of rare diseases affecting fewer than 200,000 people in the US.